Showing 891-900 of 1499 results for "".
- National Nurses Union Urges Congress to Ensure Healthcare Workers' Safety Against COVID-19https://modernaesthetics.com/news/national-nurses-union-urges-congress-to-ensure-healthcare-workers-safety-against-covid-19/2472898/National Nurses United, the largest union of registered nurses, is calling on Congress to mandate that the Occupational Safety and Health Administration promulgate an emergency temporary standard for health care workers in the third COVID-19 stimulus package currently being negotiated.
- BTL Introduces Emsella Applicator for Emsculpt Platformhttps://modernaesthetics.com/news/btl-introduces-emsella-applicator-for-emsculpt-platform/2472892/BTL is launching the new Emsella applicator with up to 2.5 Tesla (T) to treat all forms of male and female urinary incontinence. Building upon the existing clearances for Emsculpt for the abdomen, buttocks, thighs, arms and calves, the new Emsella applicator makes Emsculpt the first system to tre
- Candela Launches Exceed Medical Microneedling Systemhttps://modernaesthetics.com/news/candela-launches-exceed-medical-microneedling-system/2472878/Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch
- Revance Enters Exclusive Distribution Deal with Teoxane SA for Dermal Fillershttps://modernaesthetics.com/news/revance-enters-exclusive-distribution-deal-with-teoxane-sa-for-dermal-fillers/2472863/With the signing of a new distribution agreement, Revance Therapeutics, Inc. is now the exclusive US commercialization partner of Teoxane SA for its dermal filler products. Revance has immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (R
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Does Plastic Surgery Training Have Negative Effects on Reproductive Health?https://modernaesthetics.com/news/does-plastic-surgery-training-have-negative-effects-on-reproductive-health/2472840/Plastic surgery training takes a toll on childbearing and reproductive health, including negative effects on fertility, complications during pregnancy, and breastfeeding practices, reports a study in Plastic and Reconstructive Surgery. The study is the first to focus on reprodu
- Cynosure Rolls Out StimSure for Muscle Toning in Europe, Middle Easthttps://modernaesthetics.com/news/cynosure-rolls-out-stimsure-for-muscle-toning-in-europe-middle-east/2472839/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Physician Dispensing Exclusive: Altreno in 20g Tubehttps://modernaesthetics.com/news/physician-dispensing-exclusive-altreno-in-20g-tube/2472831/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- Results of Phase 2 Study Demonstrate Safety and Efficacy of Galderma's Proprietary Liquid Toxinhttps://modernaesthetics.com/news/results-of-phase-2-study-demonstrate-safety-and-efficacy-of-galdermas-proprietary-liquid/2472827/Results of a Phase 2 study show Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines. Galderma is now poised to advance to Phase 3 testing of the liquid formulation of botulinum toxin type A for the treatment of glabellar lines. The tr
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://modernaesthetics.com/news/fda-approves-juvderm-voluma-xc-for-mid-face-injection-via-cannula/2471976/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p